Skip to content

Royalty Pharma

US · RPRX #759 by market cap Listed 2020
56.76 +0.32 +0.57%
Live - 5344 symbols - heartbeat 270s ago · 2026-10-08 06:30
Pre-market 56.13 -1.11%
After-hours 56.76 0.00%
Market cap
25.27B
P/B
3.70
EPS
1.78
Reader sentiment Are you bullish or bearish on RPRX?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $65
    Market Newswire · 2026/7/13
  • Rating change
    UBS Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $66
    Market Newswire · 2026/8/11
  • Rating change
    TD Cowen Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $68
    Market Newswire · 2026/9/8
  • Rating change
    Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $64
    Market Newswire · 2026/5/7
  • Rating change
    J.P. Morgan Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $62
    Market Newswire · 2026/8/11
  • Rating change
    BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating
    Market Newswire · 2026/7/10
  • UBS Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $66
    Market Newswire · 2026/9/8
  • Rating change
    Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $65
    Market Newswire · 2026/8/6
  • Citi Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $70
    Market Newswire · 2026/9/9
  • BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating, Announces Target Price $63
    Market Newswire · 2026/9/24
  • Royalty Pharma(RPRX.US) Officer Sells US$5.85 Million in Common Stock
    Market Newswire · 2026/9/25
  • Rating change
    Goldman Sachs Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $66
    Market Newswire · 2026/8/7
  • Rating change
    Citi Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $66
    Market Newswire · 2026/7/16
  • Rating change
    UBS Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $57
    Market Newswire · 2026/4/21
  • Form 144 | Royalty Pharma(RPRX.US) Officer Proposes to Sell 5.85 Million in Common Stocks
    Market Newswire · 2026/9/23
  • Rating change
    J.P. Morgan Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $58
    Market Newswire · 2026/5/7
  • Rating change
    BofA Securities Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $62
    Market Newswire · 2026/5/7
  • Rating change
    Morgan Stanley Maintains Royalty Pharma(RPRX.US) With Buy Rating, Maintains Target Price $65
    Market Newswire · 2026/8/7
  • Rating change
    Goldman Sachs Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $59
    Market Newswire · 2026/5/7
  • Rating change
    Citi Maintains Royalty Pharma(RPRX.US) With Buy Rating, Raises Target Price to $70
    Market Newswire · 2026/8/6

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 06:30:58 · For reference only, not investment advice and not tailored to your situation.